Delirium Following Anticholinergic Use in Hospitalized Patients With Dementia.

IF 0.9 Q4 CLINICAL NEUROLOGY
Neurohospitalist Pub Date : 2023-04-01 Epub Date: 2022-10-25 DOI:10.1177/19418744221135914
Elijah W Hale, Zachary A Macchi, Peter S Pressman
{"title":"Delirium Following Anticholinergic Use in Hospitalized Patients With Dementia.","authors":"Elijah W Hale, Zachary A Macchi, Peter S Pressman","doi":"10.1177/19418744221135914","DOIUrl":null,"url":null,"abstract":"<p><p>We sought to explore rates of delirium amongst hospitalized patients with dementia following orders for anticholinergic medications. We hypothesized that patients receiving anticholinergic medications would have higher rates of delirium than similar, unexposed patients. We performed a retrospective chart review of 23 031 hospitalized individuals with Alzheimer's disease, vascular dementia, or unspecified dementia from 2011-2018. Rates of delirium diagnosis and haloperidol orders following anticholinergic administration were compared to patients with dementia without anticholinergic orders. Significant differences in rates of delirium and orders for haloperidol were observed between exposed and unexposed groups, with delirium having a relative risk of 2.3 and orders for haloperidol having a relative risk of 10.4. The number needed to harm for anticholinergic exposure was 5.45 for delirium and 7.09 for haloperidol. The identified difference suggests that inpatient use of anticholinergic medications may increase the risk of delirium in hospitalized patients with dementia. Despite this risk, our review suggests that anticholinergic administration is common during hospital stays among patients with dementia. Anticholinergic use may be a modifiable risk factor for delirium prevention, which could improve inpatient management of patients with dementia.</p>","PeriodicalId":46355,"journal":{"name":"Neurohospitalist","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091436/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurohospitalist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19418744221135914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We sought to explore rates of delirium amongst hospitalized patients with dementia following orders for anticholinergic medications. We hypothesized that patients receiving anticholinergic medications would have higher rates of delirium than similar, unexposed patients. We performed a retrospective chart review of 23 031 hospitalized individuals with Alzheimer's disease, vascular dementia, or unspecified dementia from 2011-2018. Rates of delirium diagnosis and haloperidol orders following anticholinergic administration were compared to patients with dementia without anticholinergic orders. Significant differences in rates of delirium and orders for haloperidol were observed between exposed and unexposed groups, with delirium having a relative risk of 2.3 and orders for haloperidol having a relative risk of 10.4. The number needed to harm for anticholinergic exposure was 5.45 for delirium and 7.09 for haloperidol. The identified difference suggests that inpatient use of anticholinergic medications may increase the risk of delirium in hospitalized patients with dementia. Despite this risk, our review suggests that anticholinergic administration is common during hospital stays among patients with dementia. Anticholinergic use may be a modifiable risk factor for delirium prevention, which could improve inpatient management of patients with dementia.

住院痴呆症患者使用抗胆碱能药物后出现谵妄。
我们试图探究遵医嘱服用抗胆碱能药物的住院痴呆症患者的谵妄发生率。我们假设,接受抗胆碱能药物治疗的患者的谵妄发生率会高于类似的未接受治疗的患者。我们对 2011-2018 年间住院的 23 031 名阿尔茨海默病、血管性痴呆或不明痴呆患者进行了回顾性病历审查。我们将谵妄诊断率和使用抗胆碱能药物后的氟哌啶醇处方率与未使用抗胆碱能药物的痴呆患者进行了比较。在暴露组和未暴露组之间观察到了谵妄率和氟哌啶醇订单率的显著差异,谵妄的相对风险为2.3,氟哌啶醇订单的相对风险为10.4。谵妄和氟哌啶醇的抗胆碱能暴露伤害所需人数分别为 5.45 和 7.09。已发现的差异表明,住院患者使用抗胆碱能药物可能会增加痴呆症住院患者发生谵妄的风险。尽管存在这种风险,但我们的研究表明,抗胆碱能药物在痴呆症患者住院期间的使用很普遍。使用抗胆碱能药物可能是预防谵妄的一个可改变的风险因素,这可以改善痴呆症患者的住院管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurohospitalist
Neurohospitalist CLINICAL NEUROLOGY-
CiteScore
1.60
自引率
0.00%
发文量
108
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信